Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals Plc ADR (NQ: CNTA )

4.510 -0.060 (-1.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Centessa Pharmaceuticals Plc ADR

< Previous 1 2 Next >
Centessa Pharmaceuticals: Q1 Earnings Insights
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
 
Via Benzinga
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Analyst Ratings for Centessa Pharmaceuticals
  Within the last quarter, Centessa Pharmaceuticals (NASDAQ:CNTA) has observed the following analyst ratings: 
Via Benzinga
Centessa Culls Early-Stage Asset For Inherited Disorder
 
Via Benzinga
BMO Capital Sees Almost 300% Upside On Centessa Stock
 
Via Benzinga
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
 
Via Benzinga
FDA Grants Orphan Drug Status To Centessa's Hemophilia B Candidate
Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. A Phase 2a... 
Via Benzinga
Morgan Stanley Downgrades Centessa Pharmaceuticals: Here's What You Need To Know
  Morgan Stanley downgraded its rating of Centessa Pharmaceuticals (NASDAQ:CNTA) to Underweight with a price target of $5.00, changing its price target from $10.00 to $5.00. Shares of Centessa... 
Via Benzinga
Goldman Sachs Maintains Neutral Rating for Centessa Pharmaceuticals: Here's What You Need To Know
  Goldman Sachs has decided to maintain its Neutral rating of Centessa Pharmaceuticals (NASDAQ:CNTA) and lower its price target from $5.00 to $4.00. Shares of Centessa Pharmaceuticals are trading down... 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
Centessa Pharmaceuticals: Q2 Earnings Insights
  Centessa Pharmaceuticals (NASDAQ:CNTA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
74 Biggest Movers From Yesterday
Gainers 
Via Benzinga
2 Big Stock Bets That Are Insiders Are Buying Now
Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
Why Did Centessa's Shares Plunge 10% Today?
Centessa Pharmaceuticals plc (NASDAQ: CNTA) announced proof-of-mechanism data from the first three subjects in Phase 1 Part B study of ZF874 in Alpha-1 Antitrypsin... 
Via Benzinga
53 Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Mid-Afternoon Market Update: loanDepot Surges After Q3 Results; Mirati Therapeutics Shares Slide
Toward the end of trading Monday, the Dow traded up 0.12% to 35,863.70 while the NASDAQ rose 0.18% to 15,525.52. The S&P, however, fell 0.10% to 4,600.81. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Dow Rises 50 Points; ANI Pharmaceuticals Shares Jump
Midway through trading Monday, the Dow traded up 0.14% to 35,871.27 while the NASDAQ rose 0.23% to 15,534.49. The S&P also fell, dropping 0.03% to 4,603.98. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks That Hit 52-Week Lows On Wednesday
Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a... 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock is seeing increased interest by traders on... 
Via Benzinga
40 Stocks Moving In Monday's Mid-Day Session
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares jumped 250% to $8.91 on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; PG&E Earnings Miss views
Following the market opening Monday, the Dow traded up 0.08% to 35,846.72 while the NASDAQ rose 0.18% to 15,527.04. The S&P also fell, dropping 0.07% to 4,602.32. The U.S. has... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.